In the wake of the increase in Current Liabilities in the fourth quarter 2026, Quick Ratio fell to 0.53 below Biomerica Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry 11 other companies have achieved higher Quick Ratio than Biomerica Inc in fourth quarter 2026. While Quick Ratio total ranking in the fourth quarter 2026 has deteriorated compared to the prior quarter from 2080 to 2146.

Explain Quick Ratio?
How much Cash & cash equivalents BMRA�s has?
What are BMRA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BMRA Quick Ratio	(May 31 2026) Q4	(Feb 28 2026) Q3	(Nov 30 2025) Q2	(Aug 31 2025) Q1	(May 31 2025) Q4
Y / Y Current Liabilities Change	42.59 %	-5.34 %	-21.05 %	-21.29 %	-21.05 %
Y / Y Cash & cash equivalent Change	-45.48 %	-56.31 %	-42.47 %	8.26 %	-42.47 %
Quick Ratio MRQ	0.53	0.86	1.38	1.8	1.38
BMRA's Total Ranking	# 2146	# 2080	# 1669	# 1972	# 1707
Seq. Current Liabilities Change	58.94 %	-10.29 %	2.78 %	-2.7 %	5.52 %
Seq. Cash & cash equivalent Change	-2.1 %	-44.31 %	-21.42 %	27.26 %	-21.55 %

Quick Ratio fourth quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 12
Healthcare Sector	# 736
Overall Market	# 2569

Quick Ratio Statistics
High	Average	Low
6.83	2.35	0.27
(Nov 30 2020)		(May 31 2016)

Financial Statements
Biomerica Inc 's Current Liabilities	$ 2 Millions	Visit BMRA's Balance sheet
Biomerica Inc 's Cash & cash equivalent	$ 1 Millions	Visit BMRA's Balance sheet
Source of BMRA's Sales		Visit BMRA's Sales by Geography

Cumulative Biomerica Inc 's Quick Ratio

BMRA's Quick Ratio for the trailling 12 Months

BMRA Quick Ratio	(May 31 2026) 12 Months	(Feb 28 2026) 12 Months	(Nov 30 2025) 12 Months	(Aug 31 2025) 12 Months	(May 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-3.47 %	-17.96 %	-20.21 %	-12.12 %	-1.8 %
Y / Y Cash & cash equivalent TTM Growth	-34.96 %	-35.38 %	-33.8 %	-42.44 %	-54.23 %
Quick Ratio TTM	1.08	1.36	1.6	1.74	1.61
Total Ranking TTM	# 1027	# 1024	# 692	# 761	# 712
Seq. Current Liabilities TTM Growth	11 %	-1.29 %	-6.37 %	-5.91 %	-5.65 %
Seq. Cash & cash equivalent TTM Growth	-11.88 %	-15.79 %	-13.97 %	1.87 %	-12.46 %

Quick ratio ranking by company, industry and sector >> Back to BMRA Financial Strength Comparisons >> Go to Compare BMRA Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q4 2026 to $2.48 millions, cumulative Quick Ratio decreased to 1.08 below the Biomerica Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Biomerica Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending third quarter 2026 at 3070.

Explain Quick Ratio?
How much Cash & cash equivalents BMRA�s has?
What are BMRA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 892
Within the Market	# 2146

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.83	2.52	0.62
(Feb 28 2021)		(Nov 30 2019)

Companies with similar Quick Ratio in the quarter ending May 31 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	May 31 2026 MRQ Cash & cash equivalent	May 31 2026 MRQ Current Liabilities
Myriad Genetics Inc	0.88	$ 115.200 Millions	$ 130.700 Millions
Biomerica Inc	0.53	$ 1.308 Millions	$ 2.481 Millions
Volitionrx Limited	0.21	$ 2.800 Millions	$ 13.493 Millions
Neogen Corporation	0.20	$ 185.500 Millions	$ 916.900 Millions
Idexx Laboratories Inc	0.15	$ 196.933 Millions	$ 1,287.665 Millions
Quidelortho Corp	0.12	$ 123.400 Millions	$ 993.400 Millions

Date modified: 2026-09-05T08:34:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.